Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study

OBJECTIVES: The primary objective was to evaluate the long-term recurrence rate following RCM-OCT-guided laser ablation of basal cell carcinomas (BCCs). The secondary objective was to assess patient-reported outcomes, including willingness to undergo the treatment again, scar acceptability, and adverse effects. METHODS: A prospective cohort study evaluated 104 patients with 148 BCCs (2017-2021). Low risk BCC subtypes and with tumor depth of ≤ 300 µm were determined using RCM-OCT, and eligible lesions underwent same-day Er:YAG laser ablation with immediate post-treatment imaging to confirm clearance. Patients underwent clinical and RCM-OCT or RCM surveillance at 6 and 12 months and annually thereafter to assess recurrence. A patient-reported questionnaire was conducted in 2023. RESULTS: Fifty-eight lesions (39.2%) in 39 patients met the criteria for laser ablation. Most lesions were located on the trunk (29/58, 50.0%), with median tumor depth and lesion size of 200 µm and 9.8 mm, respectively. Immediate post-ablation RCM-OCT demonstrated imaging-defined complete clearance after a single session in 53/58 lesions (91.4%). Residual tumors (5/58, 8.6%) were successfully treated during the same visit. Fifty-four of 58 lesions (93.1%) had at least 6 months of follow-up (median 32 months; min/max 8-70). One recurrence occurred at 53 months and was successfully retreated, corresponding to 1.04 recurrences per 100 person-years of follow-up. The patient-reported questionnaire response rate was 79.5% (31/39). Overall, 96.8% (30/31) reported acceptable scar appearance, 83.9% (26/31) were likely to choose laser ablation again (Score 1-2 of 5), and 9.7% (3/31) reported mild, transient side effects. CONCLUSIONS: RCM-OCT-guided Er:YAG laser ablation offers a "one-stop" treatment approach for selected low-risk BCCs, demonstrating low long-term recurrence rates and high patient satisfaction.

Authors

Institutions

Publication Details

Journal
Lasers in Surgery and Medicine
Published
2026-08-26
DOI
https://doi.org/10.1002/lsm.70201
Primary Topic
Nonmelanoma Skin Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study

Oriol Yélamos, Melissa Gill, Milind Rajadhyaksha, Rachel Manci et al.
Lasers in Surgery and Medicine
Nonmelanoma Skin Cancer Studies
article

Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study

Oriol Yélamos, Melissa Gill, Milind Rajadhyaksha, Rachel Manci, Nicusor V. Iftimia, Noa Kremer, Chih‐Shan Jason Chen, Cristián Navarrete‐Dechent, Miguel Córdova, Zaeem H. Nazir, Stephen W. Dusza, Ashfaq A. Marghoob, Aditi Sahu, Rozina Zeidan, Larissa M. Pastore
article en

Abstract

OBJECTIVES: The primary objective was to evaluate the long-term recurrence rate following RCM-OCT-guided laser ablation of basal cell carcinomas (BCCs). The secondary objective was to assess patient-reported outcomes, including willingness to undergo the treatment again, scar acceptability, and adverse effects. METHODS: A prospective cohort study evaluated 104 patients with 148 BCCs (2017-2021). Low risk BCC subtypes and with tumor depth of ≤ 300 µm were determined using RCM-OCT, and eligible lesions underwent same-day Er:YAG laser ablation with immediate post-treatment imaging to confirm clearance. Patients underwent clinical and RCM-OCT or RCM surveillance at 6 and 12 months and annually thereafter to assess recurrence. A patient-reported questionnaire was conducted in 2023. RESULTS: Fifty-eight lesions (39.2%) in 39 patients met the criteria for laser ablation. Most lesions were located on the trunk (29/58, 50.0%), with median tumor depth and lesion size of 200 µm and 9.8 mm, respectively. Immediate post-ablation RCM-OCT demonstrated imaging-defined complete clearance after a single session in 53/58 lesions (91.4%). Residual tumors (5/58, 8.6%) were successfully treated during the same visit. Fifty-four of 58 lesions (93.1%) had at least 6 months of follow-up (median 32 months; min/max 8-70). One recurrence occurred at 53 months and was successfully retreated, corresponding to 1.04 recurrences per 100 person-years of follow-up. The patient-reported questionnaire response rate was 79.5% (31/39). Overall, 96.8% (30/31) reported acceptable scar appearance, 83.9% (26/31) were likely to choose laser ablation again (Score 1-2 of 5), and 9.7% (3/31) reported mild, transient side effects. CONCLUSIONS: RCM-OCT-guided Er:YAG laser ablation offers a "one-stop" treatment approach for selected low-risk BCCs, demonstrating low long-term recurrence rates and high patient satisfaction.

Lasers in Surgery and Medicine
Memorial Sloan Kettering Cancer Center (US), Karolinska University Hospital (SE), Pontificia Universidad Católica de Chile (CL), Tel Aviv University (IL), SUNY Downstate Health Sciences University (US), Universidad de Alcalá (ES), Andover Eye Associates (US), Physical Sciences (United States) (US), Universitat de Barcelona (ES), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 10%
Nonmelanoma Skin Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.